Date :06/09/2007 10:56:06
Proteon Therapeutics recently completed a $12 million financing with its current investor syndicate.
Proteon, a privately held biopharmaceutical company focusing on renal and vascular diseases, will use these funds to advance its first product candidate, PRT-201, into human clinical studies in both hemodialysis vascular access and peripheral arterial disease. Proteon's investors include TVM Capital, Skyline Ventures, Prism VentureWorks and "Intersouth Partners was pleased to join the other existing investors in providing additional financing to Proteon as it advances PRT-201 toward human clinical study," says Garheng Kong of Intersouth Partners. "I personally look forward to working more closely with the Company as a new member of its Board of Directors." Bookmark with: Digg Reddit Del.icio.us Facebook Newsvine Subscribe Now! Sign Up to Exec UK now for FREE!
"Intersouth Partners was pleased to join the other existing investors in providing additional financing to Proteon as it advances PRT-201 toward human clinical study," says Garheng Kong of Intersouth Partners. "I personally look forward to working more closely with the Company as a new member of its Board of Directors."
Sign Up to Exec UK now for FREE!
28 August 2008 13:39